elhamkhani
/
Test2
/
Login
Register
TriplyDB
Test2
Browser
Triples
Insights
Schema
BETA
Class frequency
Class hierarchy
SPARQL
GraphQL
BETA
Graphs
1
Q38557670-2655D5E1-395D-4C0D-A1D8-F2C6455C0404
Q38557670-2655D5E1-395D-4C0D-A1D8-F2C6455C0404
BestRank
Statement
http://www.wikidata.org/entity/statement/Q38557670-2655D5E1-395D-4C0D-A1D8-F2C6455C0404
A fragment-based approach leading to the discovery of a novel binding site and the selective CK2 inhibitor CAM4066.
P2860
Q38557670-2655D5E1-395D-4C0D-A1D8-F2C6455C0404
BestRank
Statement
http://www.wikidata.org/entity/statement/Q38557670-2655D5E1-395D-4C0D-A1D8-F2C6455C0404
rank
NormalRank
type
BestRank
Statement
wasDerivedFrom
674d9917e914a5d8eaf2e82ec43aa69bc9a69ec6
P2860
CX-4945, an orally bioavailable selective inhibitor of protein kinase CK2, inhibits prosurvival and angiogenic signaling and exhibits antitumor efficacy.